DVAX (Dynavax Corp) Short-Term Debt to Capital

This daily price chart for Dynavax Technologies (DVAX) on the GURU.Markets platform shows a value of 0.06. The business relies on a proprietary hepatitis B vaccine, whose inclusion in medical standards ensures a stable cash flow. High capacity utilization of biopharmaceutical complexes and the upgrading of packaging lines are scaling production, although dependence on a single drug and market pressure limit growth potential.

This ratio correlates liabilities with maturities exceeding one year to equity, providing a real-time assessment of the balance between financial leverage and stability. An increase in this metric accelerates expansion in a favorable market but heightens the risk of a drawdown during a trend reversal. For a reliable pharma player like Dynavax Technologies (DVAX) with high vaccine confidence, the dynamics of short-term debt to equity confirm strategic flexibility in liquidity management.